



Form PTO-1449 Substitute

Applicant(s): Velayudhan Sahadevan

Filing Date: February 7, 2002

U.S. Patent Documents

Ref.	Number	Issue Date	Name(s)	Class	Subclass	Filing Date
(31)	4,321,208	03/23/1982	Sahadevan, V.	552/627;	552/544	09/27/1976
(33)	4,389,330	06/21/1983	Tice; Thomas R.	427/213.36;	264/4.1	10/06/1980
(34)	5,340,586	08/23/1994	Pike; Malcolm C.; S	424/426;	424/43	05/17/1993
(35)	4,244,949	01/13/1981	Gupta; Gopi N.	514/178;	A61K 031/56	04/06/1978
(36)	5,340,585	08/23/1994	Pike, Malcolm C.,	424/426;	424/42	05/17/1993
(37)	4,210,644	07/01/1980	Ewing; Larry L.; D	514/170;	514/84	02/23/1978
(38)	6,326,467	12/04/2001	Nett; Torrance M.;	530/328	350/402	04/19/2000
(40)	6,248,057	06/19/2001	Mavity; William G.	600/3;	A61N 005/0	07/27/1999

Foreign Patent Documents

Initial Number	Issue Date	Country	Class	Subclass	Translated
----------------	------------	---------	-------	----------	------------

Reference # and Other Prior Art

Ref. (Including Authors, Title, Date, Pertinent Pages, Etc.)

1. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001 page 1460: Ref # 574: Spitzweg C. Zhang S, Bergert ER, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 1999; 59(9):2136.
2. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001: page 1455: Ref # 535: Blasko JC, Walner K, Grimm PD, Ragde H. Prostate specific antigen based disease control following ultrasound guided 125 iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 1995;154:1096.
3. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001 page 1439: Ref # 288: Johansson JK, Holmberg L, Johansson S, Bergstrom R, Adami HO, Fifteen-year survival in prostate cancer: a prospective population-based study in Sweden. JAMA, 1977:277,p 467.

4. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001 page 1454: Ref # 529: Kuban DA, EL-Mahdi AM, Schellhammer PF, I-125 interstitial implantation for prostate cancer: What have we learned in 10 years, Cancer 1992; 69:2515
5. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001 page 1454: Ref.# 530: Fuks Z, Leibel SA, Wallner KE, et al The effect of local control on metastatic dissemination in carcinoma of the prostate: long term results in patients treated I-125 implantation; Int. J Radiat Oncol Biol Phys 1991; 21:537.
6. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001 page 1454: Ref: 531: Kuban DA, EL-Mahdi AM, Local control after radiation for prostatic carcinoma; Significance and assessment. Semin Radiat Oncol 1993; 3: 221
7. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001 page 1493, ref. # 285: Adolfsson J, Carstensen J. Natural course of clinically localized prostate adenocarcinoma in men less than 70 years old. J Urol 1991;146:96.
8. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001 page 1493, ref. # 287: Adolfsson J, Steineck G, Hedlund PO. Deferred treatment of clinically localized low grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. Urology 1997;50: 722.,
9. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer Principles and Practice of Oncology, 6th edition, Vol.1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001; p.1442, ref.307: Zincke H, Oesterling JE, Blute ML, et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152:1850.
10. Rosh III, M., Wallner, K., Prostate Cancer, In Textbook of Radiation Oncology; Liebel, SA, Phillips, TL, (Ed), 1998, p768-769, table 42-11.
11. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer Principles and Practice of Oncology, 6th edition, Vol.1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001, p 1452, ref. # 411: Hanks GE, Asbell S. Krall JM, et al. Outcome for lymph node dissection negative T1-b, T2 (A2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int J Radiat Oncol Biol Phys 1991; 21:1099.

12. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001 page 1493, ref. # 505: Hanks GE, Krall JM, Hanlon AL, et al. Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure, Int J Radiat Oncol Biol Phys 1994; 28:39.
13. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer, Principles and Practice of Oncology, 6th edition, Vol.1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001, p 1440, ref. # 290: Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274:626.
14. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer Principles and Practice of Oncology, 6th edition, Vol.1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001, p 1440, and Table 34.4-12, ref. # 299: Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280:975.
15. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer, Principles and Practice of Oncology, 6th edition, Vol.1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001, p 1440, ref. # 289: Adolfsson J, Steineck G, Hedlund PO. Deferred treatment of locally advanced non-metastatic prostate cancer: a long-term follow-up. J Urol 1999;161:505.
16. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer, Principles and Practice of Oncology, 6th edition, Vol.1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001, p 1440, ref. # 298: Adolfsson J. Deferred treatment of low grade stage T3 prostate cancer without distant metastases. J Urol 1993;149:326.
17. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer Principles and Practice of Oncology, 6th edition, Vol.1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001, p 1435.
18. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer, Principles and Practice of Oncology, 6th edition, Vol.1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001, p1439, ref. 291: Aus G, Hugosson J, Norlen L. Long-term survival and mortality in prostate cancer treated with noncreative intent. J Urol 1995; 154:460.
19. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer Principles and Practice of Oncology, 6th edition, Vol.1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001, p 1447.
20. Rosh III, M., Wallner, K., Prostate Cancer, In Textbook of Radiation Oncology; Liebel, SA, Phillips, TL, (Ed), 1998, p768, ref. 127: Blasko JC, Grimm PD, Ragade H: Brachytherapy and organ preservation in the management of the carcinoma of the prostate. Semin Radiat Oncol. 1993; 3: 240.

21. Rosh III, M., Wallner, K., Prostate Cancer, In Textbook of Radiation Oncology; Liebel, SA, Phillips, TL, (Ed).,1998, p 768.
22. Rosh III, M., Wallner, K., Prostate Cancer, In Textbook of Radiation Oncology; Liebel, SA, Phillips, TL, (Ed).,1998, p 763-764).
23. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer Principles and Practice of Oncology, 6th edition, Vol.1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001, Page 1453, Ref # 415: Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1988; 41:491.
24. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer Principles and Practice of Oncology, 6th edition, Vol.1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed) 2001;Page 1454, Ref # 520: Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy, in localized prostate cancer, Int J Radiat Oncol Biol Phys. 1997; 37:247.
25. Rosh III, M., Wallner, K., Prostate Cancer, In Textbook of Radiation Oncology; Liebel, SA, Phillips, TL, (Ed).,1998, p 777, Table 42-23.
26. Rosh III, M., Wallner, K., Prostate Cancer, In Textbook of Radiation Oncology; Liebel, SA, Phillips, TL, (Ed).,1998, p 777, Table 42-23, ref # 297: Laverdiere J, Gomez JL, Cusan L, et al; Beneficial effects of combination therapy administered prior to and following external beam radiation therapy in localized prostate cancer, Int J Radiat Oncol Biol Phys. 1997; 37:247.
27. Rosh III, M., Wallner, K., Prostate Cancer, In Textbook of Radiation Oncology; Liebel, SA, Phillips, TL, (Ed).,1998, page 778, ref. 28: Bolla, M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and Goserelin. N Engl J Med. 1997;337:295.
28. Rosh III, M., Wallner, K., Prostate Cancer, In Textbook of Radiation Oncology; Liebel, SA, Phillips, TL, (Ed).,1998, page 776-777, Table 42-23, ref. 301: Pilepich MV, Caplan R, Byhardt RX, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Oncology Group 8531. J Clin Oncol. 1997;15:1013.
29. Rosh III, M., Wallner, K., Prostate Cancer, In Textbook of Radiation Oncology; Liebel, SA, Phillips, TL, (Ed), 1998, page 776-777, Table 42-23, ref. 280: Pilepich, MV, Krall JM, Al-Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45:616.

30. Jensen EV, Estrogen binding and clinical response of breast cancer: In Cancer Medicine; Holland J.F., Frei III, E. (Ed), 1974, page 922.
32. Pharmacia and Upjohn Company, Depo-Provera, Physicians Desk Reference, PDR, 51, 1997, p2079
39. Carroll P.R., Lee, K.L., Fuks, Z.Y., Kantoff, P. W., Cancer of the Prostate, In Cancer, Principles and Practice of Oncology, 6th edition, Vol.1; DeVita, Jr., Hellman. S, and Rosenberg, (Ed), 2001, p.1464, Ref. 651:Smith DC, Redman BG, Flaherty LE, et al. A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer. Urology 1998; 52(2):257.
41. Anderson LL, Weaver KA, Physics of Brachytherapy, In Textbook of Radiation Oncology; Liebel, SA, Phillips, TL, (Ed), 1998, p 156
42. Anderson LL, Weaver KA, Physics of Brachytherapy, In Textbook of Radiation Oncology; Liebel, SA, Phillips, TL, (Ed), 1998, p 152
43. Norplant System, Wyeth Ayerst Laboratories, Physicians Desk Reference, PDR, 51, 1997, p2868

Examiner

Date Considered